Indoco Remedies Limited
INDOCO · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹333.41.
Piotroski F-score 4/9 — quality of earnings & balance sheet.
Investability checklist
- ✕ROE above 15%-10.1%
- ✕Low debt (D/E < 0.5)1.17x
- ✕Positive free cash flow
- ✓Revenue growth > 10%22%
- –Earnings growing
- ✕Net margin ≥ 10%-5.2%
- ✕Current ratio > 1.51.13
- ✓Below our fair value
- ✓Margin of safety ≥ 20%
- ✕Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✕Altman Z in safe zoneZ 1.92
- ✕Piotroski ≥ 74/9
1-year price
EOD · 2026-06-16Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Quarterly results
Annual financials
Shareholding
Promoter holding via insider stake; institutional via reported holdings.
Analyst views
Key fundamentals
SWOT snapshot
Weaknesses
- •Low return on equity (-10.1%).
- •Price below its 200-day moving average (downtrend).
Opportunities
- •Revenue growing (22% YoY).
- •Trading in our value buy zone versus sector peers.
- •Trades ~79% below our estimated fair value.
About Indoco Remedies Limited
Indoco Remedies Limited manufactures and markets formulations and active pharmaceutical ingredients in India and internationally. It offers products for gastrointestinal, anti-infectives, respiratory, stomatological, vitamins/minerals/nutrients, urological, ophthal/ontological, dermatology, pain/analgesic, cardiac, anti-diabetic, and gynaecological therapeutic areas. The company also provides branded generics comprising analgesic tablets and topical preparations; anti-hyperte
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.